Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18621526 | SUPRAMOLECULAR IONIZABLE LIPID MOLECULES WITH HETEROATOMIC TUNING FOR NUCLEIC ACID DELIVERY | March 2024 | June 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18402112 | BAMBOO CHARCOAL POWDER-BASED FALSE EYELASHES AND PREPARATION PROCESS THEREOF | January 2024 | March 2025 | Allow | 14 | 4 | 1 | No | No |
| 18244155 | TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASES | September 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18462701 | FIBRIN PARTICLES AND METHODS OF MAKING THE SAME | September 2023 | May 2025 | Allow | 20 | 1 | 1 | No | No |
| 18351952 | COLORING ULTRAVIOLET PROTECTIVE AGENT | July 2023 | June 2025 | Abandon | 23 | 2 | 1 | No | No |
| 18445165 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | May 2023 | November 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18310034 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | May 2023 | April 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18308597 | Octreotide Depot Formulation with Constantly High Exposure Levels | April 2023 | October 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18445035 | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof | March 2023 | March 2025 | Abandon | 24 | 3 | 0 | No | No |
| 18086058 | NOVEL FORMULATION OF MELOXICAM | December 2022 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18057607 | DENDRIMER COMPOSITIONS AND THEIR USE IN TREATMENT OF DISEASES OF THE EYE | November 2022 | December 2024 | Abandon | 24 | 2 | 1 | No | No |
| 17803703 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | October 2022 | September 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 17797819 | NERVE SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | August 2022 | February 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17817030 | Mechano-Sensitive Microcapsules For Drug Delivery | August 2022 | November 2024 | Allow | 28 | 3 | 1 | Yes | No |
| 17859537 | POLYETHYLENIMINE NANOPARTICLES AND METHODS OF USING SAME | July 2022 | April 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17845208 | PHOSPHOCALCIC CEMENT COMPOSITION COMPRISING BLOOD | June 2022 | March 2025 | Abandon | 33 | 4 | 1 | Yes | No |
| 17668272 | ANTI-TUMORAL COMPOUND AND RELATIVE PRODUCTION PROCESS | February 2022 | November 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17583498 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | January 2022 | May 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17581366 | Novel nanobubble that contains epilepsy medicine. The bubble polarizes in presence of the electric surge generated in the brain during an epilepsy attack and automatically discharges the medicine at the time and the site of the attack, stopping the seizure in its infancy without any external intervention. The bubble releases just enough medication into the bloodstream, significantly reducing side effects. | January 2022 | March 2024 | Abandon | 26 | 1 | 0 | Yes | No |
| 17560820 | IMMUNOSTIMULATORY LIPOPLEX, PHARMACEUTICAL COMPOSITION INCLUDING IMMUNOSTIMULATORY LIPOPLEX, AND USES THEREOF | December 2021 | April 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17644215 | MOISTURIZING COMPOSITIONS AND USES THEREOF | December 2021 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17534146 | MICROPARTICLES AND NANOPARTICLES HAVING SULFATE GROUPS ON THE SURFACE | November 2021 | May 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17524211 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | November 2021 | January 2025 | Abandon | 39 | 4 | 1 | No | No |
| 17517621 | Microbubble-extracellular vesicle complexes | November 2021 | September 2024 | Allow | 35 | 3 | 1 | Yes | No |
| 17516289 | Synthetic Scaffolds for Metastasis Detection | November 2021 | September 2024 | Abandon | 34 | 2 | 1 | No | Yes |
| 17512124 | TUNABLE IMMUNE RESPONSIVE BIODEGRADABLE ARGININE-BASED POLY(ESTER AMIDE)S AND METHODS OF MAKING AND USING SAME | October 2021 | April 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17503553 | MULTI-PHASE ORAL COMPOSITION FOR TOOTH WHITENING | October 2021 | September 2024 | Allow | 35 | 2 | 0 | No | No |
| 17598558 | METHOD OF PREPARING NANOPLATEFORM-BASED DIAGNOSTIC AGENT FOR SELECTIVELY STAINING OF INFLAMMATORY ABNORMAL TISSUE OR TUMOR TISSUE | September 2021 | June 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17479400 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEROXISOMAL DISORDERS AND LEUKODYSTROPHIES | September 2021 | March 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17472502 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE | September 2021 | July 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17460743 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | August 2021 | February 2023 | Allow | 17 | 0 | 1 | Yes | No |
| 17305916 | TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASES | July 2021 | May 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17421607 | Manganese Ferrite Nanoparticles for Use as MRI Contrast Agents and Magnetohypothermia Agents | July 2021 | May 2025 | Abandon | 46 | 3 | 1 | No | No |
| 17421005 | DRUG DELIVERY PLATFORM USING W/O/W-TYPE TRIOLEIN EMULSION PROMOTIVE OF BLOOD-BRAIN BARRIER OPENING | July 2021 | December 2024 | Abandon | 41 | 4 | 1 | Yes | No |
| 17419937 | POLYMERSOMES FUNCTIONALISED WITH MULTIPLE LIGANDS | June 2021 | February 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17416592 | SLEEP MODULATION AGENT | June 2021 | May 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17343095 | MEDICAL ITEM FOR PREVENTION AND TREATMENT OF EAR INFECTION | June 2021 | August 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17311679 | FIBRIN-TARGETED POLYMERIZED SHELL LIPID MICROBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | June 2021 | December 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17298436 | DENDRIMER FOR THERAPY AND IMAGING | May 2021 | June 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17295457 | PHOTOCHEMICALLY INDUCED CONJUGATION OF RADIOMETALS TO SMALL MOLECULES, PEPTIDES AND NANOPARTICLES IN A SIMULTANEOUS ONE-POT REACTION | May 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17290906 | ALGINIC ACID-BASED INJECTABLE HYDROGEL SYSTEM | May 2021 | April 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17290337 | Methods for Synthesis of Radionuclide Complex | April 2021 | June 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17240117 | FUSOGENIC LIPOSOMES FOR SELECTIVE IMAGING OF TUMOR CELLS | April 2021 | August 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17300227 | Formulated and/or co-furmulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof | April 2021 | December 2022 | Allow | 20 | 0 | 1 | Yes | No |
| 17285281 | Nanostructured Lipid Gel, Method for Preparation and Use | April 2021 | November 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17285194 | RADIOLIGANDS FOR IMAGING THE LPA1 RECEPTOR | April 2021 | November 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17208405 | Makeup Cosmetic Having Improved Impregnated Material | March 2021 | May 2024 | Abandon | 37 | 2 | 0 | Yes | No |
| 17271562 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | February 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17270946 | RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND | February 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17177370 | Compositions And Methods For Attracting Insects | February 2021 | May 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17171836 | Octreotide Depot Formulation with Constantly High Exposure Levels | February 2021 | June 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17153123 | METHOD OF PREPARING A COSMETIC COMPOSITION | January 2021 | April 2025 | Abandon | 51 | 2 | 0 | No | Yes |
| 17255242 | TUNABLE IMMUNE RESPONSIVE BIODEGRADABLE ARGININE-BASED POLY(ESTER AMIDE)S AND METHODS OF MAKING AND USING SAME | December 2020 | March 2022 | Abandon | 15 | 1 | 1 | No | No |
| 16974306 | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof | December 2020 | December 2022 | Allow | 24 | 0 | 1 | Yes | No |
| 17123941 | ENCAPSULATED CELLS PRODUCING CYTOCHROME P450 AND METHODS OF USE THEREOF | December 2020 | June 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17116357 | MITOCHONDRIAL COPPER DEPLETION REPROGRAMS THE METABOLISM OF TRIPLE NEGATIVE BREAST CANCER | December 2020 | May 2023 | Abandon | 29 | 0 | 1 | No | No |
| 16972798 | TMEM-MCD IN THE MINIMALLY INVASIVE ASSESSMENT OF THE ACTIVITY STATUS OF TMEM IN ITS DISSEMINATION OF TUMOR CELLS | December 2020 | July 2024 | Abandon | 43 | 5 | 1 | Yes | No |
| 17106141 | METHODS AND DEVICES FOR LYMPHATIC TARGETING | November 2020 | November 2024 | Abandon | 47 | 5 | 0 | No | Yes |
| 16951736 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | November 2020 | September 2022 | Abandon | 22 | 0 | 1 | Yes | No |
| 17099568 | NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF | November 2020 | May 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17090347 | METHOD FOR IMPROVING SKIN WHITENING POWER OF A SKIN WHITENING AGENT | November 2020 | September 2023 | Abandon | 34 | 2 | 0 | Yes | No |
| 17051507 | DRUG DELIVERY | October 2020 | October 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17083601 | PEPTIDE-NANOPARTICLE CONJUGATES | October 2020 | September 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 17075758 | Epilatory Compositions | October 2020 | December 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 17075882 | Epilatory Compositions | October 2020 | December 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 17064348 | STABLE EMULSIFIED GEL COMPOSITION HAVING A HIGH CONCENTRATION OF ACTIVE COMPONENTS | October 2020 | June 2023 | Abandon | 32 | 3 | 1 | Yes | No |
| 17044189 | STEREOCOMPLEX OF OLIGOLACTIC ACID CONJUGATES IN MICELLES FOR IMPROVED PHYSICAL STABILITY AND ENHANCED ANTITUMOR EFFICACY | September 2020 | September 2022 | Abandon | 23 | 3 | 1 | Yes | No |
| 16981432 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | September 2020 | December 2023 | Allow | 39 | 0 | 1 | Yes | No |
| 17017473 | NOVEL FORMULATION OF MELOXICAM | September 2020 | February 2023 | Abandon | 29 | 1 | 0 | No | No |
| 16979059 | METHOD FOR OBTAINING PROTEINS OR A RICH-PROTEIN EXTRACT FROM ALGAE, EXTRACTS AND USES THEREFORE | September 2020 | November 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16978479 | Dyes for Analysis of Soluble Protein Aggregates or Misfolded Protein Oligomers | September 2020 | June 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16970975 | POROUS EMBOLIZATION MICROSPHERES COMPRISING DRUGS | August 2020 | November 2024 | Abandon | 51 | 2 | 1 | No | No |
| 16989041 | Complex, Preparation Methods and Application Thereof | August 2020 | January 2024 | Abandon | 41 | 4 | 1 | No | No |
| 16962196 | NANOSYSTEMS AS SELECTIVE VEHICLES | July 2020 | January 2023 | Abandon | 30 | 2 | 1 | No | No |
| 16958962 | LIPOCALIN-TYPE PROSTAGLANDIN D2 SYNTHASE PRODUCTION PROMOTING AGENT | June 2020 | November 2023 | Abandon | 41 | 2 | 1 | Yes | No |
| 16906695 | POLYMERIC BILE ACID NANOPARTICLES AS ANTI-INFLAMMATORY AGENTS | June 2020 | June 2025 | Abandon | 59 | 3 | 1 | No | Yes |
| 16898830 | MOISTURIZING COMPOSITIONS AND USES THEREOF | June 2020 | September 2021 | Allow | 15 | 1 | 1 | Yes | No |
| 16772113 | AMPHIPHILIC BLOCK COPOLYMERS, MICELLES, AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | June 2020 | April 2025 | Abandon | 58 | 9 | 1 | Yes | No |
| 16894618 | ANTIMICROBIAL COMPOSITION | June 2020 | November 2023 | Allow | 41 | 4 | 1 | Yes | No |
| 16768760 | FIBRIN PARTICLES AND METHODS OF MAKING THE SAME | June 2020 | June 2023 | Allow | 36 | 4 | 1 | Yes | No |
| 16883250 | TARGETED THERAPEUTICS | May 2020 | July 2023 | Abandon | 37 | 2 | 1 | No | Yes |
| 16872526 | CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURE AND USE THEREOF | May 2020 | November 2022 | Abandon | 30 | 3 | 0 | No | No |
| 16761974 | CHALLENGE TEST FOR DIAGNOSING A SUBTYPE OF AUTISM SPECTRUM DISEASE | May 2020 | December 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16856849 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | April 2020 | May 2021 | Allow | 13 | 1 | 0 | Yes | No |
| 16753447 | MECHANICAL PROCESSING OF BIOPOLYMERS | April 2020 | November 2023 | Abandon | 43 | 5 | 0 | Yes | No |
| 16605120 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | April 2020 | June 2023 | Allow | 44 | 4 | 1 | Yes | No |
| 16828222 | MUCUS-PENETRATING BUDESONIDE NANOSUSPENSION ENEMA FOR LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE | March 2020 | July 2023 | Abandon | 40 | 3 | 1 | Yes | No |
| 16820574 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE | March 2020 | October 2021 | Abandon | 19 | 1 | 0 | No | No |
| 16800090 | COSMETIC COMPOSITIONS CONTAINING AN ALKOXYSILANE AND A SILSESQUIOXANE RESIN | February 2020 | February 2022 | Allow | 23 | 2 | 1 | No | No |
| 16632317 | NANOPARTICLES, METHODS AND USES THEREOF | January 2020 | March 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16623448 | POLYETHYLENIMINE NANOPARTICLES AND METHODS OF USING SAME | December 2019 | July 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16620252 | B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED NANOPARTICLES | December 2019 | August 2023 | Abandon | 44 | 2 | 1 | Yes | No |
| 16701644 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MUSHROOM EXTRACT OR POWDER | December 2019 | February 2023 | Allow | 38 | 3 | 0 | Yes | Yes |
| 16616718 | Silver Palladium and Silver Platinum Nanoparticles Useful as Antimicrobial and Anticancer Agents | November 2019 | March 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16615327 | ULTRASOUND RESONANCE TRIGGERING OF PAYLOAD RELEASE FROM MINIATURIZED DEVICES | November 2019 | March 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16605601 | LIPOSOME COMPOSITIONS AND USES THEREOF | October 2019 | January 2024 | Abandon | 51 | 4 | 1 | Yes | No |
| 16564770 | SUPPLEMENT COMPOSITION | September 2019 | October 2023 | Allow | 50 | 4 | 1 | Yes | Yes |
| 16545263 | LOCAL ANESTHETIC SOLUTION FOR DENTAL AND/OR CONTRAST MEDIA USE | August 2019 | December 2021 | Abandon | 28 | 2 | 0 | No | No |
| 16540445 | PHOSPHOCALCIC CEMENT COMPOSITION COMPRISING BLOOD | August 2019 | March 2022 | Allow | 31 | 3 | 0 | Yes | No |
| 16485493 | EXOSOME-BASED NANOPARTICLE COMPOSITE AND METHOD FOR PREPARING THE SAME | August 2019 | July 2023 | Abandon | 47 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WESTERBERG, NISSA M.
With a 26.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WESTERBERG, NISSA M works in Art Unit 1618 and has examined 880 patent applications in our dataset. With an allowance rate of 24.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner WESTERBERG, NISSA M's allowance rate of 24.9% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WESTERBERG, NISSA M receive 2.79 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WESTERBERG, NISSA M is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.2% benefit to allowance rate for applications examined by WESTERBERG, NISSA M. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 6.3% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 13.2% of cases where such amendments are filed. This entry rate is in the 8% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 59.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 53.9% of appeals filed. This is in the 20% percentile among all examiners. Of these withdrawals, 43.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 73.2% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.